Nemes Rush Group’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Nemes Rush Group’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3	Closed	-$2	–	772
2024 Q4	$2	Hold	3	–	–	﹤0.01%	728
2024 Q3	$27	Hold	3	–	–	﹤0.01%	605
2024 Q2	$23	Hold	3	–	–	﹤0.01%	601
2024 Q1	$27	Buy	+3	New	+$26	﹤0.01%	663
2023 Q4	–	Sell	-4	Closed	-$22	–	700
2023 Q3	$22	Hold	4	–	–	﹤0.01%	651
2023 Q2	$25	Buy	+4	New	+$26	﹤0.01%	672

Nemes Rush Group's ONCT Position: Q1 2025 in Review

Nemes Rush Group sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2025, closing a stake of 3 shares — an estimated $2 sold.

Nemes Rush Group first reported a position in ONCT in Q2 2023 and held it in 6 quarters. The position peaked at $27 in Q3 2024. 0 funds tracked by Wall St. Rank hold ONCT as of Q1 2025.

Nemes Rush Group reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Nemes Rush Group sold 3 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $2.
Nemes Rush Group first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2023 and held it in 6 quarters.
Nemes Rush Group's Oncternal Therapeutics, Inc. Common Stock position peaked at $27 in Q3 2024.
0 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Nemes Rush Group's 13F filing for Q1 2025, filed 7 May 2025.